IJCRR - vol 08 issue 08, April, 2016
CORRELATION OF COAGULATION PROFILE IN LIVER DISEASE PATIENTS IN A TERTIARY CARE HOSPITAL
Author: G. K. Tripathi, Ankita A. Katara, Shweta V. Awasthi, Shashank V. Srivastava
Objective: To determine the coagulation abnormalities among liver disease patients admitted in a tertiary care hospital of Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh (India) for a period of 1 year (January 2015 to December 2015). Methods: Patients were labeled as liver disease patients on the basis of Liver Function Tests (LFT) done in the hospital at the time of admission. Patients blood were collected in sodium citrate and plain vaccutainer for coagulation tests [prothrombin time (PT), activated partial thromboplastin time (aPTT)] and liver function tests respectively. The prothrombin time ratio was calculated and then used to calculate the international normalized ratio. Following parameters were included in Liver Function Test, serum bilirubin, SGOT, SGPT, ALP, Total Protein and serum albumin. Results: Total number of cases studied in a period of 1 year (January 2015 to December 2015) were 311. In 284(91.3%) cases both LFT and coagulation profile were done. In 261 (83.9%) cases (out of total 311 cases) coagulation tests were normal and in 50 (16.1%) cases coagulation tests were found to be deranged. Out of these 50 cases, PT was raised in 44(100%) cases, APTT was raised in 21(95.4%) cases and both PT and APTT were raised in 15(93.75%) cases. Conclusion: Coagulation abnormalities were profound patients with chronic liver diseases. In case of acute liver disease ,usually PT( Prothrombin Time) is increased, but aPTT (activated partial thromboplastin time)is found to be normal. aPTT (activated partial thromboplastin time)is usually increased in chronic liver diseases, but the PT(Prothrombin Time) prolongation is usually not seen in initial stages of chronic liver disease until the stage of liver fibrosis and cirrhosis is reached. Nevertheless, these parameters (PT and aPTT) were still widely used as prognostic markers in liver disease patients..
Keywords: Coagulation abnormalities, Chronic liver disease, PT, aPTT
G. K. Tripathi, Ankita A. Katara, Shweta V. Awasthi, Shashank V. Srivastava. CORRELATION OF COAGULATION PROFILE IN LIVER DISEASE PATIENTS IN A TERTIARY CARE HOSPITAL International Journal of Current Research and Review. vol 08 issue 08, April, 01-03
1. Borowski M, Furie BC, Bauminger S et al. (1986) Prothrombin requires two sequential metal dependent conformational transitions to bind phospholipid. Conformation- specific antibodies directed against the phospholipid-binding site on prothrombin.JBiol Chem261 (32),14969-14975.
2. Caraceni P, Van Thiel DH. Acute liver failure.Lancet 1995;345:163-169.
3. Dickson ER, Grambsch PM, Fleming TR, Fischear LD, Langworthy A. Progformer. Hepatology1989;10:1-7.
4. Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methyl prednisolone therapy in patients with severe alcoholic hepatitis. Ann Intern Med 1989;110:685- 690.
5. Michal J, Carey , George M. Rodgers . Disseminated Intravascular Coagulation: Clinical and Laboratory Aspects, American Journal of hematology1998; 73: 65-73.
6. Xavier Forns ,SergiAmpurdanès, Josep M. Llovet, and et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2003; 36 : 986 – 992.
7. TTOCO2.4 Synthetic Function. 2.4.2 The liver and coagulation, page 255-263.
8. Rverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thrombheamost 2006; 4: 717-20.
9. Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis 2009; 13: 55-61.
10. Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J 2008; 84: 177-81.